arrow
A

Anna Morena D'Alise

nouscom srl
H指数:23
被引数:2,509

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tissue-Specific Silencing of Synthetic mRNAs By De-Targeting Elements Maps Vaccination-Competent Tissues, and Allows Cas9 De-Immunization

通过靶向元件沉默合成mRNAs以映射具有疫苗接种能力的组织,并允许Cas9脱免疫化

2026-07-290
OAAI
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial

Nous 209的新抗原疫苗用于Lynch综合征携带者的癌症预防: 1b/2期试验

2026-01-160
OAAI
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses

基于病毒载体的个性化疫苗接种的I期试验引发了强大的新抗原特异性抗肿瘤T细胞反应

2024-03-207
OAAI
Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity

载体辅助微环境编程 (VAMP): 用MVA病毒表达IL-12对TME进行重编程,以实现有效的抗肿瘤活性

2023-04-282
OAAI
Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection

基于腺病毒的疫苗促进新抗原特异性CD8 T细胞干细胞和肿瘤排斥

2022-08-1040
OA
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
2021-11-257
OAAI
Initial results from a phase I study of Nous-209, an off-the-shelf viral vectored immunotherapy encoding 209 shared frame shift peptide neoantigens, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability
2021-09-012
OAAI
VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens' Prediction

金星,一种提高新生物预测准确性的新选择方法

2021-08-0912
OAAI
A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability
2020-09-1557
OAAI
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans
2020-06-1731
OAAI
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
2019-06-1979
OAAI